Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.

Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research14 Mar 2005Cited by 157 (Europe PMC)

PMID15940379DOI10.1359/jbmr.050309PepBankPUB-15940379

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide markedly increased histomorphometric bone formation indices versus alendronate at 6 months.
In plain wordsIn women with osteoporosis, teriparatide increased bone formation indices more than alendronate at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation indices at 6 months
Study
n = 17
Comparator
Alendronate 10 mg
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 6 monthsAs given in this study (human).
Source sentences
Summary
Histomorphometric indices of bone formation were significantly and markedly greater in the teriparatide group than in the alendronate group at 6 and 18 months
2 context sentences(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Summary · context
Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7).
Report a problemFND-1594037901
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, bone resorption indices were significantly greater with teriparatide than alendronate at 6 months.
In plain wordsIn women with osteoporosis, teriparatide produced higher bone resorption indices than alendronate at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone resorption indices at 6 months
Study
n = 17
Comparator
Alendronate 10 mg
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 6 monthsAs given in this study (human).
Source sentences
Summary
whereas indices of bone resorption were only significantly greater in the teriparatide group than in the alendronate group at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Summary · context
Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7).
Report a problemFND-1594037903
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide markedly increased histomorphometric bone formation indices versus alendronate at 18 months.
In plain wordsIn women with osteoporosis, teriparatide increased bone formation indices more than alendronate at 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation indices at 18 months
Study
n = 15
Comparator
Alendronate 10 mg
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Source sentences
Summary
Histomorphometric indices of bone formation were significantly and markedly greater in the teriparatide group than in the alendronate group at 6 and 18 months
2 context sentences(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Summary · context
Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7).
Report a problemFND-1594037902
04HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, bone resorption indices were not significantly greater with teriparatide than alendronate at 18 months.
In plain wordsIn women with osteoporosis, bone resorption indices were not significantly higher with teriparatide than alendronate at 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone resorption indices at 18 months
Study
n = 15
Comparator
Alendronate 10 mg
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Source sentences
Summary
whereas indices of bone resorption were only significantly greater in the teriparatide group than in the alendronate group at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Summary · context
Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7).
Report a problemFND-1594037904
05HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, degree of mineralization did not differ between teriparatide and alendronate groups.
In plain wordsIn women with osteoporosis, bone mineralization did not differ between teriparatide and alendronate groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDegree of mineralization
Study
n: not reported in source
Comparator
Alendronate 10 mg
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once dailyAs given in this study (human).
Source sentences
Summary
The degree of mineralization was lower at 18 months than at 6 months with treatment in both groups but was not different between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Summary · context
Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7).
Report a problemFND-1594037908
06HumanObservational studyEfficacy outcome
In women with osteoporosis receiving teriparatide, bone formation was significantly lower at 18 months than at 6 months.
In plain wordsIn women with osteoporosis, bone formation during teriparatide treatment was lower at 18 months than at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone formation over time
Study
n: not reported in source
Comparator
6 months of teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 6 and 18 monthsAs given in this study (human).
Source sentences
Summary
Bone formation and activation frequency were significantly lower at 18 months compared with 6 months in the teriparatide group, returning to levels comparable with untreated postmenopausal women.
2 context sentences(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Summary · context
Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7).
Report a problemFND-1594037905
07HumanObservational studyEfficacy outcome
In women with osteoporosis receiving teriparatide, activation frequency was significantly lower at 18 months than at 6 months.
In plain wordsIn women with osteoporosis, bone remodeling activation during teriparatide treatment was lower at 18 months than at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseActivation frequency over time
Study
n: not reported in source
Comparator
6 months of teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 6 and 18 monthsAs given in this study (human).
Source sentences
Summary
Bone formation and activation frequency were significantly lower at 18 months compared with 6 months in the teriparatide group, returning to levels comparable with untreated postmenopausal women.
2 context sentences(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Summary · context
Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7).
Report a problemFND-1594037906
08HumanObservational studyEfficacy outcome
In postmenopausal women receiving teriparatide, bone formation at 18 months returned to levels comparable with untreated postmenopausal women.
In plain wordsIn women receiving teriparatide, bone formation after 18 months was comparable with untreated postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone formation versus untreated women at 18 months
Study
n: not reported in source
Comparator
Untreated postmenopausal women
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Source sentences
Summary
Bone formation and activation frequency were significantly lower at 18 months compared with 6 months in the teriparatide group, returning to levels comparable with untreated postmenopausal women.
1 context sentence(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Report a problemFND-1594037909
09HumanObservational studyEfficacy outcome
In postmenopausal women receiving teriparatide, activation frequency at 18 months returned to levels comparable with untreated postmenopausal women.
In plain wordsIn women receiving teriparatide, activation frequency after 18 months was comparable with untreated postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeActivation frequency versus untreated women at 18 months
Study
n: not reported in source
Comparator
Untreated postmenopausal women
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Source sentences
Summary
Bone formation and activation frequency were significantly lower at 18 months compared with 6 months in the teriparatide group, returning to levels comparable with untreated postmenopausal women.
1 context sentence(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Report a problemFND-1594037910

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

10HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving teriparatide, peak histomorphometric bone formation indices coincided with peak PINP levels.
In plain wordsIn women receiving teriparatide, peak bone formation indices coincided with peak PINP levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableBone formation peak association with PINP
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the teriparatide group, the peak in histomorphometric bone formation indices coincided with peak levels for N-terminal propeptide of type I collagen, a biochemical marker of bone formation.
2 context sentences(design, population, supporting numbers)
Summary · context
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 microg with alendronate 10 mg on bone histomorphometry.
Summary · context
Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1594037907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.